Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
PHASE1CompletedINTERVENTIONAL
Enrollment
75
Participants
Timeline
Start Date
December 31, 2001
Primary Completion Date
July 31, 2007
Conditions
Adult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic OligodendrogliomaAdult Brain Stem GliomaAdult Diffuse AstrocytomaAdult EpendymoblastomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Mixed GliomaAdult Myxopapillary EpendymomaAdult OligodendrogliomaAdult Pilocytic AstrocytomaAdult Primary Hepatocellular CarcinomaAdult SubependymomaAdvanced Adult Primary Liver CancerAdvanced Malignant MesotheliomaMale Breast CancerRecurrent Adenoid Cystic Carcinoma of the Oral CavityRecurrent Adult Brain TumorRecurrent Adult Primary Liver CancerRecurrent Anal CancerRecurrent Basal Cell Carcinoma of the LipRecurrent Bladder CancerRecurrent Breast CancerRecurrent Cervical CancerRecurrent Colon CancerRecurrent Esophageal CancerRecurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityRecurrent Inverted Papilloma of the Paranasal Sinus and Nasal CavityRecurrent Lymphoepithelioma of the NasopharynxRecurrent Lymphoepithelioma of the OropharynxRecurrent Malignant MesotheliomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal CavityRecurrent Mucoepidermoid Carcinoma of the Oral CavityRecurrent Non-small Cell Lung CancerRecurrent Ovarian Epithelial CancerRecurrent Pancreatic CancerRecurrent Prostate CancerRecurrent Rectal CancerRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Verrucous Carcinoma of the LarynxRecurrent Verrucous Carcinoma of the Oral CavityStage II Esophageal CancerStage II Pancreatic CancerStage III Esophageal CancerStage III Pancreatic CancerStage IIIB Non-small Cell Lung CancerStage IV Adenoid Cystic Carcinoma of the Oral CavityStage IV Anal CancerStage IV Basal Cell Carcinoma of the LipStage IV Bladder CancerStage IV Breast CancerStage IV Colon CancerStage IV Esophageal CancerStage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityStage IV Inverted Papilloma of the Paranasal Sinus and Nasal CavityStage IV Lymphoepithelioma of the NasopharynxStage IV Lymphoepithelioma of the OropharynxStage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal CavityStage IV Mucoepidermoid Carcinoma of the Oral CavityStage IV Non-small Cell Lung CancerStage IV Ovarian Epithelial CancerStage IV Pancreatic CancerStage IV Prostate CancerStage IV Rectal CancerStage IV Salivary Gland CancerStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Verrucous Carcinoma of the LarynxStage IV Verrucous Carcinoma of the Oral CavityStage IVA Cervical CancerStage IVB Cervical CancerUnspecified Adult Solid Tumor, Protocol SpecificUntreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions
DRUG
erlotinib hydrochloride
Given orally
OTHER
laboratory biomarker analysis
Correlative studies
Trial Locations (1)
60606
Cancer and Leukemia Group B, Chicago
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00030498 - Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction | Biotech Hunter | Biotech Hunter